Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Asia Deal Watch: SV Investment And Orange Grove Will Team Up On New Company Effort

Executive Summary

Takeda spins out Oak Hill Bio, Lupin and Axantia will co-develop filgrastim biosimilar and Xbiome licenses skin ulcer candidate from Aurealis.

You may also be interested in...



Dr Reddy’s Brings In Range Of Mature Novartis Brands In India

With an ‘India First’ strategy previously communicated, Dr Reddy’s Laboratories has brought in several Novartis India Established Medicines. “We intend to evaluate capabilities to maintain business continuity,” the company says.

It’s Deal Time: Aurobindo on M&A, Divestment Path

What value do PE funds see in Aurobindo Pharma’s injectables business as the company looks for a partner? Why is Aurobindo looking for acquisitions in India as it sets a domestic revenue target of $133m in three years from the formulations business? Scrip takes a look.

China's First Biotech M&A Deal In 2022 Signals Busy Season Ahead?

CSPC acquires a little-known Guangzhou biotech to kick-start China's pharma sector consolidation in 2022, a key goal outlined in the country's recent 14th Five-Year Plan.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145901

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel